XML 27 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Interim Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 187 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
Cash flows from (used in): Operating activities:      
Net income (loss) $ 2,715 $ 4,669 $ (101,256)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 0 0 1,404
Non-cash Cadherin Biomedical Inc. litigation expense 0 0 1,187
(Gain)/loss on derivative warrant (3,327) (5,680) (8,146)
Unrealized foreign exchange loss   10 36
Amortization of deferred lease inducements 0 0 (412)
Loss on impairment of capital assets 0 0 386
Non-cash severance expense 0 0 168
Stock options issued to consultants 0 0 896
Stock options issued to employees 0 0 10,095
Acquired in-process research and development 0 0 13,094
Changes in non-cash working capital 34 (47) (73)
Net cash used in operating activities (578) (1,048) (82,621)
Investing activities:      
Purchase of capital assets 0 0 (1,440)
Disposal of capital assets 0 0 115
Release of restricted cash 0 0 190
Restricted cash 0 0 (209)
Proceeds from sale of assets 0 0 24
Purchase of short-term investments 0 0 (22,148)
Redemption of short-term investments 0 0 22,791
Investment in Cadherin Biomedical Inc. 0 0 (166)
Acquired intellectual property rights 0 0 (640)
Net cash used in investing activities 0 0 (1,483)
Financing activities:      
Conversion of long-term debt to equity 0 0 68
Long-term debt repayments 0 0 (65)
Capital lease repayments 0 0 (8)
Issuance of common stock, net of issue costs 0 0 86,443
Registration expense 0 0 (465)
Financing expenses 0 0 (544)
Proceeds from convertible note 0 0 3,017
Other liability repayments 0 0 (87)
Security deposits 0 0 35
Proceeds from exercise of stock options 0 0 51
Net cash from used in financing activities 0 0 88,445
Effect of exchange rate changes on cash and cash equivalents 0 124 378
Net change in cash and cash equivalents (578) (924) 4,719
Cash and cash equivalents - Beginning of period 5,297 5,947 0
Cash and cash equivalents - End of period $ 4,719 $ 5,023 $ 4,719